KR20190031439A - Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체 - Google Patents

Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체 Download PDF

Info

Publication number
KR20190031439A
KR20190031439A KR1020187035166A KR20187035166A KR20190031439A KR 20190031439 A KR20190031439 A KR 20190031439A KR 1020187035166 A KR1020187035166 A KR 1020187035166A KR 20187035166 A KR20187035166 A KR 20187035166A KR 20190031439 A KR20190031439 A KR 20190031439A
Authority
KR
South Korea
Prior art keywords
ser
val
leu
thr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187035166A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 웨이너
사라 엘리엇
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아, 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority to KR1020237013950A priority Critical patent/KR20230058733A/ko
Publication of KR20190031439A publication Critical patent/KR20190031439A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187035166A 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체 Ceased KR20190031439A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237013950A KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
US62/332,377 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013950A Division KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Publications (1)

Publication Number Publication Date
KR20190031439A true KR20190031439A (ko) 2019-03-26

Family

ID=60203626

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187035166A Ceased KR20190031439A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체
KR1020257000876A Pending KR20250011241A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체
KR1020237013950A Ceased KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257000876A Pending KR20250011241A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체
KR1020237013950A Ceased KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Country Status (12)

Country Link
US (1) US20190192692A1 (enExample)
EP (1) EP3452106A4 (enExample)
JP (3) JP7311113B2 (enExample)
KR (3) KR20190031439A (enExample)
CN (1) CN109789224A (enExample)
AU (2) AU2017261292B2 (enExample)
BR (1) BR112018072697A2 (enExample)
CA (1) CA3023089A1 (enExample)
EA (1) EA201892524A1 (enExample)
MX (2) MX2018013523A (enExample)
SG (2) SG11201809786TA (enExample)
WO (1) WO2017192933A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712536A1 (en) 2019-03-19 2020-09-23 LG Electronics Inc. Air purifying apparatus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
WO2022155404A1 (en) * 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562968T3 (da) * 2001-11-14 2013-10-28 Janssen Biotech Inc Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
DK1960430T3 (da) * 2005-12-09 2015-01-05 Ucb Pharma Sa Antistofmolekyler der har specificitet for humant il-6
AU2007282023B2 (en) * 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US8034344B2 (en) * 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
CA2818813C (en) * 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712536A1 (en) 2019-03-19 2020-09-23 LG Electronics Inc. Air purifying apparatus

Also Published As

Publication number Publication date
AU2017261292A1 (en) 2018-12-20
SG10202011023YA (en) 2020-12-30
KR20250011241A (ko) 2025-01-21
JP7311113B2 (ja) 2023-07-19
AU2024203109A1 (en) 2024-05-30
EP3452106A1 (en) 2019-03-13
WO2017192933A1 (en) 2017-11-09
CN109789224A (zh) 2019-05-21
KR20230058733A (ko) 2023-05-03
JP2025147175A (ja) 2025-10-06
CA3023089A1 (en) 2017-11-09
EA201892524A1 (ru) 2019-04-30
AU2017261292B2 (en) 2024-06-06
BR112018072697A2 (pt) 2019-02-19
MX2018013523A (es) 2019-06-10
SG11201809786TA (en) 2018-12-28
EP3452106A4 (en) 2020-01-08
JP2019518074A (ja) 2019-06-27
MX2025009846A (es) 2025-09-02
US20190192692A1 (en) 2019-06-27
JP2023086734A (ja) 2023-06-22

Similar Documents

Publication Publication Date Title
AU2017261374B2 (en) DNA antibody constructs for use against pseudomonas aeruginosa
JP2023086734A (ja) Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
KR102375324B1 (ko) 인플루엔자 바이러스를 표적으로 하는 dna 단일클론 항체
KR20220020229A (ko) Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도
US20240376179A1 (en) Dna antibody constructs for use against middle east respiratory syndrome coronavirus
JP2023126321A (ja) ライム病に対する使用のためのｄｎａ抗体構築物
HK40009046A (en) Dna monoclonal antibodies targeting il-6 and cd126
US20230340082A1 (en) Dna antibody constructs for use against rotavirus
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
EA042308B1 (ru) Днк-моноклональные антитела, нацеленные на il-6
HK40013455A (en) Dna antibody constructs for use against lyme disease
WO2019152602A1 (en) Structurally modified flavivirus dmabs
WO2019152607A1 (en) Nucleic acid antibody constructs for use against ebola virus
HK40009043A (zh) 靶向检查点分子的dna单克隆抗体
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
HK40011839A (en) Dna antibody constructs for use against pseudomonas aeruginosa

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181204

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220202

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221122

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230424

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20221122

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220801

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190103

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230522

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230424

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20221122

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220801

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220202

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190103

X601 Decision of rejection after re-examination